NetworkNewsBreaks

TuesdayJun 17, 2025 12:38 pm

NetworkNewsBreaks – FingerMotion Inc. (NASDAQ: FNGR) Partners with Qingling Motors to Develop Intelligent Commercial Vehicle Solutions 

FingerMotion (NASDAQ: FNGR) announced that its subsidiary, JiuGe Technology, is collaborating with Qingling Motors to co-develop intelligent vehicle solutions aimed at improving efficiency and sustainability in commercial mobility. The partnership targets high-demand sectors like logistics and emergency response, with Qingling leading vehicle design and compliance while JiuGe contributes software integration and smart system development. A joint technical taskforce has been formed to accelerate innovation, share intellectual property, and support long-term growth, including international expansion and remote service ecosystems. To view the full press release, visit https://nnw.fm/QzQq7 About FingerMotion Inc. FingerMotion is an evolving technology company with a core competency in…

Continue Reading

TuesdayJun 17, 2025 9:10 am

NetworkNewsBreaks – Intelligent Bio Solutions Inc. (NASDAQ: INBS) CEO Highlights Fingerprint Drug Testing on BioMedWire Podcast

Intelligent Bio Solutions (NASDAQ: INBS) CEO Harry Simeonidis joined the latest episode of The BioMedWire Podcast to discuss the company’s rapid, non-invasive drug screening platform and global expansion strategy. Simeonidis detailed how the company’s fingerprint-based technology detects drug use through sweat, enabling faster and more affordable workplace screening. With current deployments in about 20 countries and an FDA application under review, Intelligent Bio Solutions is targeting U.S. market entry in the second half of 2025 and expects to scale through distributor partnerships and targeted marketing. To view the full article, visit https://nnw.fm/B3ENr About Intelligent Bio Solutions Inc. Intelligent Bio Solutions…

Continue Reading

TuesdayJun 17, 2025 9:00 am

NetworkNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) and AccurKardia Join Forces to Advance Remote Cardiac Monitoring

HeartBeam to integrate AccurECG(TM), AccurKardia’s FDA-cleared ECG analysis software Collaboration enhances HeartBeam’s commercial offering with automated arrhythmia insights Combined platform aims to improve cardiac care access and speed time to diagnosis HeartBeam (NASDAQ: BEAT) announced a strategic collaboration with AccurKardia, a leader in automated ECG diagnostics, to integrate its FDA-cleared AccurECG(TM) software into HeartBeam’s cable-free, credit card-sized 3D ECG device. The partnership unites two innovators in ambulatory cardiac monitoring to create a more scalable, accessible solution for arrhythmia detection and management. HeartBeam’s device captures electrical signals in three non-coplanar directions and synthesizes them into a 12-lead ECG for remote use.…

Continue Reading

MondayJun 16, 2025 3:21 pm

NetworkNewsBreaks – ROTH’s 15th Annual London Conference to Showcase Market Trends, Compelling Investment Opportunities

Roth Capital Partners (“ROTH”), www.roth.com, today announced the agenda and details for its 15th Annual London Conference, which is slated to take place at the Four Seasons Hotel at Park Lane in London on June 24-26, 2025. The event is designed to foster meaningful dialogue between institutional investors and C-suite leaders and senior executives from approximately 80 companies with a strong focus on the sustainability and technology sectors. "We look forward to hosting the 15th edition of our flagship London conference," said ROTH’s Executive Chairman Byron Roth. "This event creates a unique environment for our corporate clients to engage directly…

Continue Reading

MondayJun 16, 2025 10:20 am

NetworkNewsBreaks – Lantern Pharma Inc. (NASDAQ: LTRN) Reports Complete Response in Advanced NSCLC Patient in HARMONIC(TM) Trial

Lantern Pharma (NASDAQ: LTRN) announced a remarkable clinical outcome in its Phase 2 HARMONIC(TM) trial, with a 70-year-old never-smoker with advanced non-small cell lung cancer (NSCLC) achieving a durable complete response following treatment with LP-300 in combination with standard chemotherapy. The patient, who had previously failed three lines of therapy including Keytruda(R), radiation, and Tagrisso(R), initially saw a 57% tumor reduction and later achieved full resolution of lung and adrenal lesions. Nearly two years after treatment initiation, the patient remains progression-free and has experienced no clinically significant adverse reactions across 21 cycles. This sustained response underscores the potential of LP-300, developed…

Continue Reading

MondayJun 16, 2025 9:48 am

NetworkNewsBreaks – SolarBank Corporation (NASDAQ: SUUN) (Cboe CA: SUNN) (FSE: GY2) Advances 2.4 MW Community Solar Project in Nova Scotia 

SolarBank (NASDAQ: SUUN) (Cboe CA: SUNN) (FSE: GY2) announced progress on its 2.4 MW DC Sydney project in Nova Scotia, reinforcing its expansion in the Canadian community solar market. Valued at $4.57 million and developed in partnership with AI Renewable Flow-through Fund and Trimac Engineering, the project is expected to produce 2,730 MWh of clean energy annually—enough to power 221 homes and offset 1,900 tons of CO₂. Construction is slated for spring 2026, with SolarBank serving as developer and EPC contractor. The company anticipates near-term engineering revenues and long-term income from operations and maintenance contracts while supporting Nova Scotia’s goal…

Continue Reading

MondayJun 16, 2025 9:20 am

NetworkNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Forms Investor Relations Partnership With astr Partners

NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage biopharmaceutical company, and its subsidiary HOPE Therapeutics announced a strategic investor relations partnership with astr partners, a boutique firm specializing in life sciences. The collaboration comes as NRx advances toward two NDA filings, an ANDA submission, and expands its interventional psychiatry clinic acquisitions. Led by veterans of The Trout Group, astr will support NRx and HOPE with investor targeting, message development, earnings prep, and institutional outreach to enhance visibility and engagement. To view the full press release, visit https://nnw.fm/hL3y3 About NRx Pharmaceuticals, Inc. NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics based on…

Continue Reading

MondayJun 16, 2025 9:00 am

NetworkNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) VALID-ECG Study Confirms Diagnostic Accuracy of Synthesized 12-Lead ECG

HeartBeam’s credit card-sized device demonstrated 93.4% diagnostic agreement with standard ECGs VALID-ECG study results presented at Heart Rhythm Society conference Company eyes U.S. commercialization pending FDA clearance HeartBeam (NASDAQ: BEAT) announced its synthesized 12-lead ECG met clinical endpoints in the VALID-ECG pivotal study, achieving 93.4% diagnostic agreement with standard ECGs for arrhythmia assessment. The findings, presented by Dr. Thomas Deering of Piedmont Heart Institute at the Heart Rhythm Society’s annual meeting in San Diego, validate HeartBeam’s compact, patient-friendly ECG technology. The study compared ECG intervals and amplitudes between HeartBeam’s synthesized output and simultaneously collected standard ECGs in 198 patients across…

Continue Reading

FridayJun 13, 2025 3:35 pm

NetworkNewsBreaks – SolarBank Corp.’s (NASDAQ: SUUN) (Cboe CA: SUNN) (FSE: GY2) Forest Hill Rd Project Adds to Growing Development Pipeline

Disseminated on behalf of SolarBank Corporation SolarBank (NASDAQ: SUUN) (Cboe CA: SUNN) (FSE: GY2) was featured in a recent article that discussed its momentum with the development of its Forest Hill Rd solar project in upstate New York. “The 4.584 megawatt DC installation will operate as a community solar facility, contributing renewable energy to the local grid and offering cost savings to approximately 540 homes,” reads the article. “The project adds to SolarBank’s growing development pipeline, which now exceeds one gigawatt and already includes several solar projects in upstate New York. It also represents continued expansion in the U.S. market at…

Continue Reading

FridayJun 13, 2025 3:03 pm

NetworkNewsBreaks – Driving the Future of Powersports: Massimo Group’s (NASDAQ: MAMO) Bold Strategy for Market Growth

As the powersports and recreational watercraft industries experience a notable upswing, Massimo Group (NASDAQ: MAMO) is taking a proactive approach through domestic manufacturing, strategic partnerships, and product diversification—initiatives that position the company to capitalize on emerging opportunities. Fueled by growing consumer enthusiasm for outdoor recreation and the multi-purpose appeal of vehicles like those in Massimo’s lineup, the global powersports market—valued at $37.96 billion in 2023—is expected to reach $60.51 billion by 2032. Founded in 2009 and headquartered in Garland, Texas, Massimo Motor has aligned itself with these trends through a broad product line that includes UTVs, ATVs, e-bikes and pontoon boats, catering…

Continue Reading